Imagin Medical (CSE: IME) (OTCQB: IMEXF), With Their Advanced i/Blue(TM) Imaging System, Closes Second Tranche of Convertible Note Offering

• Imagin Medical is a surgical company focused on developing its i/Blue(TM) Imaging System, employing patented ultrasensitive imaging technology
• The i/Blue(TM) Imaging System is system compatible; system attaches to most endoscopes
• The company recently closed the second tranche for the amount of US$1,415,500 of the Convertible Note offering

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive surgical procedures. Imagin Medical is run by an experienced management team that is preparing their i/Blue(TM) Imaging System for the industry. An FDA approval process is underway.

The company’s patented ultrasensitive imaging product, the i/Blue(TM) Imaging System, based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.

The Patented i/Blue(TM) Imaging System

White light cystocopy does not always discern cancer from healthy tissue. The company hopes to overcome this handicap using its advanced patented ultrasensitive imaging product, the i/Blue(TM) Imaging System (https://ibn.fm/0qXzk).

Imagin Medical uses Blue Light technology that combines the improved image quality of blue light with the location orientation that white light provides. The device uses an already FDA-approved contrast agent, that is administered through a catheter one hour before the surgery.

The i/Blue(TM) Imaging System is compatible with most endoscopes through the plug-and-play method. The surgeon can simultaneously view both white and blue light video streams in a single frame and in real-time on the surgical monitor, without having to toggle between the two images. The company believes this breakthrough technology will advance the accuracy and efficiency of bladder cancer detection and removal. And potentially reduce bladder cancer recurrence rates and as well as healthcare costs (https://ibn.fm/Qg9R3).

In a recent announcement made by Imagin Medical, the company stated that it has closed the second tranche of US$1,415,500 of the Convertible Note offering. Total Convertible Note amount of $2,165,500 raised earlier this year (https://ibn.fm/KyKxg).

Imagin Medical’s Focus on Surgical Imaging Market

The global endoscopy market is valued at $46B. Imagin’s bladder cancer target is estimated to be a $400M slice of this market. The demand for improved visualization during Minimally Invasive Surgery (“MIS”) has increased manifold in recent years. MIS is less painful, offers speedy recovery, and cost-savings.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.